« Back
Home /
Cevipabulin

Cevipabulin

Item no.	HY-14949-50mg
Manufacturer	MedChem Express
CASRN	849550-05-6
Amount	50 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Colorectal Cancer Brain Cancer
Type	Inhibitors
Specific against	other
Purity	99.86
Citations	[1]Beyer CF, et al. TTI-237: a novel microtubule-active compound with in vivo antitumor activity. Cancer Res. 2008 Apr 1;68(7):2292-300.\|[2]Beyer CF, et al. The microtubule-active antitumor compound TTI-237 has both paclitaxel-like and vincristine-like properties. Cancer Chemother Pharmacol. 2009 Sep;64(4):681-9.
Smiles	C[C@@]([H])(C(F)(F)F)NC1=C(C2=C(F)C=C(OCCCNC)C=C2F)C(Cl)=NC3=NC=NN13
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	TTI-237
Shipping Condition	Cool pack
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Microtubule/Tubulin
Shipping Temperature	Blue Ice
Storage Conditions	-20°C, 3 years (Powder)
Molecular Weight	464.82
Product Description	Cevipabulin (TTI-237) is an oral, microtubule-active antitumor compound and inhibits the binding of [3H] vinblastine to tubulin, with an IC50 of 18-40 nM for cytotoxicity in human tumor cell line[1][2].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 100 mg/mL (ultrasonic)
Manufacturer - Pathway	Cell Cycle/DNA Damage; Cytoskeleton
Clinical information	Phase 1

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-14949-50mg-safety-datasheet.pdf